Welcome to the e-CCO Library!

P629: Evolution of disease phenotype, time to biological therapy and medium-, long-term surgery rates in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
Year: 2022
Source: ECCO'22
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(1,5);
Created: Friday, 11 February 2022, 3:56 PM
P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. D'Ugo1,2*, F. Romano2, G. Bagaglini2, L. Fazzolari2, B. Sensi2, A. Di Giorgio2, G. Sica2

Created: Thursday, 21 February 2019, 9:14 AM
P629: Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ylisaukko-oja, T.(1);Af Björkesten, C.G.(2)*;Erbel, A.(2);Nuutinen, H.(3);Jussila, A.(4);Molander, P.(2);Koskela, R.(5);Blomster, T.(5);Pajala, M.(6);Ilus, T.(4);Haiko, P.(7);Kovac, B.(7);Silvola, S.(7);Smith, S.(1);Jokelainen, J.(1);Sipponen, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P629: Rural-urban inequities in Inflammatory Bowel Disease health care access: a population-based retrospective cohort study from a Western Canadian Province
Year: 2021
Source: ECCO'21 Virtual
Authors: Peña-Sánchez, J.N.(1);Osei, J.A.(1);Rohatinsky, N.(2);Lu, X.(3);Risling, T.(2);Boyd, I.(4);Wicks, K.(5);Quintin, C.L.(6);Dickson, A.(7);Fowler, S.A.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P629: The initial trough concentration at 36 h after starting tacrolimus is important for the personalised medicine strategy in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Hida*1, K. Watanabe2, T. Miyazaki1, Y. Yokoyama2, M. Kawai1, T. Takagawa1, K. Kamikozuru1, T. Sato2, K. Fujimoto1, R. Koshiba1, K. Kojima1, S. Nakamura1

Created: Friday, 22 February 2019, 9:41 AM
P630 Complete endoscopic remission is not only associated with higher mucosal concentrations of 5-aminosalicylic acid but also with N-acetyl-5-aminosalicylic acid in patients with ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Fukuda1, M. Naganuma1, K. Takabayashi2, Y. Hagihara1, S. Tanemoto1, E. Nomura1, Y. Yoshimatsu1, S. Sugimoto1, K. Nanki1, S. Mizuno1, Y. Mikami1, K. Fukuhara3, T. Suzino1, M. Mutaguchi2, N. Inoue3, H. Ogata2, Y. Iwao3, T. Kanai1

Created: Thursday, 30 January 2020, 10:12 AM
P630: A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Walmsley*1, A. McCombie2, M. Barclay2, N. Visesio1, C. Ho3, S. Brown4, K. Rosser5, S. Inns4, A. Gray6, H. Regenbrecht6, T. Langlotz6, M. Schultz6

Created: Friday, 22 February 2019, 9:41 AM
P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Noguier*, C. Montaillier, L. Colombeau, T. Ticaud, E. Parussini

Created: Thursday, 21 February 2019, 9:14 AM
P630: Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)
Year: 2021
Source: ECCO'21 Virtual
Authors: Gutiérrez Casbas, A.(1);Zapater, P.(2);Ricart, E.(3);González-Vivó, M.(4);Gordillo, J.(5);Olivares, D.(6);Vera-Mendoza, I.(7);Mañosa, M.(8);P. Gisbert, J.(9);Aguas, M.(10);Sánchez-Rodríguez, E.(11);Boscá, M.(12);Laredo, V.(13);Camps, B.(14);Marín-Jíménez, I.(15);Zabana, Y.(16);Martín-Arranz, M.D.(17);Muñoz, R.(18);Navarro-Llavat, M.(19);Sierra, E.(20);Madero, L.(21);Vela, M.(22);Pérez-Calle, J.(23);Sainz, E.(24);Calvet, X.(25);Sicilia, B.(26);Morales, V.(27);Bermejo, F.(28);Fernández-Salazar, L.(29);Van Domselaar, M.(30);De Castro, L.(31);Rodríguez, C.(32);Muñoz-Villafranca, C.(33);Lorente, R.(34);Rivero, M.(35);Iglesias, E.(36);Herreros, B.(37);Barreiro-de-Acosta, M.(38);Domènech, E.(39);Francés, R.(40);
Created: Wednesday, 2 June 2021, 4:12 PM
P630: Systematic review and meta-analysis: Diagnostic delay and the subsequent impact on the disease course of adult Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Jayasooriya, N.(1,2,3);Ballie , S.(1,2);Blackwell, J.(1,2);Creese, H.(3);Bottle, R.(3);Petersen, I.(4,5);Saxena, S.(3);Pollok, R.C.(1,2,3);
Created: Friday, 11 February 2022, 3:56 PM
P630: The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nozaki R., Goto H., Tsuji Y., Takano S., Yamada K., Takano M.

Created: Wednesday, 20 February 2019, 10:36 AM
P630: Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.W.(1)*;Lim, A.(2);Lacerda, A.P.(3);Allegretti, J.R.(4);Watanabe, K.(5);Lukin, D.(6);Dubenco, E.(3);Ford, S.(3);Oomen, J.(3);Zhou, Q.(3);Liu, J.(3);Louis, E.(7);
Created: Friday, 14 July 2023, 11:05 AM
P631 Predictors of vedolizumab treatment persistence in bio-naïve ulcerative colitis patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T.E. Ritter1, H.E. Sarles2, S.A. Mehta3, L.J. Van Anglen3

Created: Thursday, 30 January 2020, 10:12 AM
P631: Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. S. Dulai*1, S. Singh1, N. Vande Casteele1, J. Meserve1, A. Winters2, S. Chablaney2, S. Aniwan3, P. Shashi4, G. Kochhar4, A. Weiss5, J. L. Koliani-Pace6, Y. Gao7, B. S. Boland1, J. T. Chang1, D. Faleck2, R. Hirten2, R. Ungaro2, D. Lukin5, K. Sultan7, D. Hudesman8, S. Chang8, M. Bohm9, S. Varma9, M. Fischer9, E. Shmidt10, A. Swaminath11, N. Gupta12, M. Rosario13, V. Jairath14, L. Guizzetti15, B. G. Feagan14, C. A. Siegel6, B. Shen4, S. Kane3, E. V. Loftus Jr3, W. J. Sandborn1, B. E. Sands2, J-F. Colombel2, K. Lasch13, C. Cao13

Created: Friday, 22 February 2019, 9:41 AM
P631: Food triggers in inflammatory bowel disease from the patients’ and doctors’ perspective
Year: 2021
Source: ECCO'21 Virtual
Authors: Cappello, M.(1);Guida, L.(1);Di Giorgio, F.M.(1);Busacca, A.(1);Carrozza, L.(1);Ciminnisi, S.(1);Almasio, P.L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P631: Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases. -A nationwide, retrospective study-
Year: 2022
Source: ECCO'22
Authors: Kutschera, M.(1);Ritschl, V.(2);Berthold, R.(3);Stamm, T.(2);Kiener, H.(4);Maier, H.(5);Reinisch, W.(1);Benka, B.(6);Novacek, G.(1);
Created: Friday, 11 February 2022, 3:56 PM
P631: Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Louis, E.(1)*;Sebastien, S.(2);Siegmund, B.(3);Bossuyt, P.(4);Danese, S.(5);de Boer, N.(6);Loftus, E.(7);Moum, B.(8);Peyrin-Biroulet, L.(9);Schreiber, S.(10);Zhou, J.(11);Wernicke, J.(11);Angellotti, E.(12);Siegel, C.(13);
Created: Friday, 14 July 2023, 11:12 AM
P631: Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bibani N., Yakoubi M., Sabbah M., Trad D., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Created: Wednesday, 20 February 2019, 10:36 AM
P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide study
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cañete1,2*, M. Mañosa2,3, M. Barreiro-de Acosta4, E. Iglesias5, R. Ríos6, R.C. González-Sueyro7, A. Villoria3,8, M. Navarro-Llavat9, I. Rodriguez-Lago10, C. Taxonera11, P. Navarro12, P. López13, L. Ramos14, M. Van Domselaar15, A. Algaba16, M.J. Casanova3,17, C. Muñoz-Villafranca18, R. Pajares19, M. Sampedro20, M. Rivero21, P.G. Delgado-Guillena22, A. Hernández23, C. Aràjol24, A.F. Pordomingo25, M. Piqueras26, E. Sáinz-Arnau27, O. Benítez-Leiva3,28, P. Ramírez-de la Piscina29, E. Cabré2,3, E. Domènech2,3

Created: Thursday, 21 February 2019, 9:14 AM
P632 Vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of response: A systematic review and meta-analysis of real-world evidence
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Varghese1, D. Patel2, S. Martin2, M. Luo3, L. Ursos4, R. Lirio5, S. Wang3

Created: Thursday, 30 January 2020, 10:12 AM